Moonlight Tx nets $5M in Series A round

Moonlight Tx nets $5M in Series A round

With the investment, Georgia Tech-launched Moonlight Therapeutics will evaluate its first food allergy treatment in clinical trials.
 
How and why: Called MOON101, the treatment is a skin stamp (above) that delivers drugs through needles small enough to be painless. The platform’s first drug is aimed at people with peanut allergies.
 
What’s unique: MOON101 overcomes skin barriers to deliver an allergen to an area of the skin that has an abundance of immune cells. It’s a complex drug delivery system in a simple stamp that’s applied daily. 

The latest backers: Portal Innovations, Inc. co-led the investment round, with AllerFund and Invest Georgia also investing. Based in Chicago, Portal Innovations held its grand opening for its Georgia HQ on Sept. 24 in Atlanta.
 
Significance: Clinical trials for MOON101 can now begin sooner.
 
Read the Hypepotamus article on the investment >
See GRA’s recent feature on Moonlight Therapeutics >

February 20, 2026
Recognition highlights Brookhaven’s commitment to life sciences growth and biomanufacturing readiness Brookhaven, GA, Feb. 18, 2026 – The City of Brookhaven has been designated a BioReady Gold Community by Georgia Life Sciences, the state’s leading life sciences membership organization. The BioReady Community program evaluates a community’s preparedness to support life sciences development across key areas, including zoning and permitting, utilities and infrastructure, workforce readiness, and coordination among local government and economic development partners. The Gold distinction represents a high level of readiness and alignment with industry needs. “Achieving Gold BioReady status underscores Brookhaven’s commitment to being a competitive destination for life sciences innovation and manufacturing,” said Aaron Szarowicz, City of Brookhaven Economic Development Director. “This designation reflects the intentional investments and partnerships we’ve built to support companies as they scale and create high-quality jobs in our community.” Brookhaven’s BioReady assessment highlighted the City’s modern infrastructure, strategic location within metro Atlanta, access to a skilled workforce, and collaborative approach between City leadership, regional partners, and the business community. Together, these assets position Brookhaven to support companies across the life sciences value chain—from research and development to scale-up and manufacturing. The BioReady rating system evaluates communities across three tiers—Bronze, Silver, and Gold—based on their readiness to attract and support life sciences facilities. Through these ratings, Georgia Life Sciences helps municipalities better showcase biotech-zoned sites, strengthen infrastructure planning, and clearly identify life sciences-friendly locations. This approach enables communities like Brookhaven to compete more effectively for private investment and job creation. Georgia Life Sciences works to advance innovation, strengthen the workforce pipeline, and grow Georgia’s life sciences economy through the BioReady Community program, modeled after MassBio’s nationally recognized rating system which assesses a community’s readiness to host life sciences facilities based on zoning practices and infrastructure capacity. For more information on the non-profit, membership-based organization, visit www.galifesciences.org . For more information about Brookhaven’s economic development initiatives, visit www.BrookhavenGA.gov/EconDev . ### Media Contact: Ann Marie Quill, Assistant Communications Director 404-205-3832 AnnMarie.Quill@BrookhavenGA.gov
February 18, 2026
Georgia Life Sciences Releases “Pathways & Partnerships: A Roadmap for Georgia’s Life Sciences Sector”
February 17, 2026
by Maria Saporta February 9, 2026
MORE POSTS